QIAseq Targeted DNA Panels

Digital DNA sequencing to confidently detect low-frequency variants

S_1084_5_GEN_V2
Configure at GeneGlobe
Find or custom design the right target-specific assays and panels to research your biological targets of interest.

QIAseq Targeted DNA Panel (12)

Cat. No. / ID:   333502

Kit containing ALL reagents (except indexes) for targeted DNA sequencing; fixed panel for 12 samples; less than 100 genes
1.794.000,00 KRW
Log in To see your account pricing.
Panel
QIAseq Targeted DNA Panel
QIAseq Targeted DNA HC Panel
QIAseq Targeted DNA IO Panel
QIAseq Targeted DNA Booster Panel
Samples
12
96
QIAseq Targeted DNA Panels are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
Configure at GeneGlobe
Find or custom design the right target-specific assays and panels to research your biological targets of interest.

Features

  • Digital sequencing enabled by molecular barcodes to remove PCR duplicates
  • Complete Sample to Insight solution streamlines the workflow
  • Compatibility with low-quality DNA enables efficient sequencing of FFPE and cfDNA samples
  • Minimal DNA input to preserve precious samples
  • Optimized buffers and conditions to achieve high coverage of GC-rich regions

Product Details

The QIAseq targeted DNA Panels have been developed as a complete Sample to Insight solution to enable digital DNA sequencing by utilizing molecular barcodes. Digital DNA sequencing is a unique approach to detect low-frequency variants with high confidence by overcoming the issues of PCR duplicates, false positives and library bias.

Each panel is a one-box, NGS platform-agnostic solution that contains all the necessary components to construct libraries from enriched genomic targets. Primer design is based on QIAseq Enrichment Technology, in which each genomic target is enriched by one target-specific primer and one universal primer – a strategy that removes conventional two target-specific primer design restriction and reduces the amount of required primers. All primers required for a panel are pooled into an individual primer pool to reduce panel handling and the number of pools required for enrichment and library construction. Platform-specific indexes, which are contained in a separate box, allow the multiplexing of up to 384 samples per sequencing run.

Performance

  • Accuracy: Innovative digital sequencing (incorporating molecular barcodes) eliminates PCR duplication and amplification artifacts to detect low-frequency variants with high confidence (see figure Principle of molecular barcodes).
  • Specificity: The unique combination of our proprietary primer design algorithm and rigorous testing of every primer assay guarantees high specificity and accurate results.
  • Uniformity: The QIAseq Targeted DNA Panel workflow has been optimized to deliver highly uniform sequencing results, to ensure sequencing capacity is utilized very efficiently (see figure Uniformity).
  • Sensitivity: Digital DNA sequencing approach is optimized to deliver high confidence in calling low-frequency DNA variants. Over 90% sensitivity for 1% NA12878 SNP and indel on typical coding region with false positive less than 15 per mega base region when variants are detected with tiled primer design to cover complete coding region of each gene.
  • Universality: The chemistry used in the QIAseq targeted DNA panels and workflow is compatible with both regular and GC-rich genomic regions, allowing one to achieve 100% coverage of genes rich in GC content such as CEBPA and CCND1 (see figure: coverage of GC-rich genomic regions)
  • Flexibility: The QIAseq targeted DNA panels offer a high degree of flexibility in content and sample multiplexing. Several cataloged panels have been developed for a wide range of applications. One can also build a custom panel for a specific content, or extend the contents of an existing cataloged panel. Up to 384 samples can be multiplexed using the QIAseq indexes.

Principle

PCR duplicates are a major issue in targeted DNA sequencing, since, through PCR amplification, they turn unique DNA molecules into identical DNA molecules that cannot be distinguished from each other. In addition, errors from PCR amplification and sequencing process may also be present in final reads that lead to false positive variants in sequencing results. This, in turn, results in the inability to confidently call DNA variants present at low frequencies in the starting DNA material. To overcome the issue of PCR duplicates and amplification artifacts, the QIAseq Targeted DNA Panels use digital sequencing by incorporating molecular barcodes into the starting DNA material before any amplification takes place, thereby preserving the uniqueness of the starting DNA molecules and overcoming the issues of PCR duplicates, false positives and library bias.

Procedure

The entire workflow of the QIAseq targeted DNA panels to go from extracted DNA to sequencing-ready libraries can be completed in 9 hours (see figure Workflow). Extracted DNA is fragmented, genomic targets are molecularly barcoded and enriched, and libraries are constructed. Sequencing files can be fed into the QIAseq pipeline, a cloud-based data analysis pipeline, which will filter, map and align reads, as well as count unique molecular barcodes associated with targeted genomic regions, and call variants with a barcode-aware algorithm. This data can then be fed into IVA or QCI for interpretation.

Applications

The QIAseq targeted DNA panels can be used to call a variety of DNA variants from a wide range of sample types for numerous applications.

DNA variants:

  • SNVs
  • Small indels
  • CNVs

Sample types:

  • FFPE
  • Plasma/serum
  • Fresh or frozen tissue
  • Cell lines

Applications:

  • Profiling of DNA variants in solid and hematologic malignancies
  • Hotspot detection in solid tumors
  • Examination of variants in mitochondrial DNA
  • Pain and ADME Pharmacogenomics
  • Human identity and paternity testing
  • Assessment of germline mutations for inherited diseases
  • Profiling of all exonic bases in BRCA 1 and BRCA2

Supporting data and figures

Resources

Brochures & Guides (6)

Next-generation sequencing using QIAGEN’s QIAseq – a powerful tool for human identification


State-of-the-art technologies to fast-track and streamline NGS workflows
Advanced sample collection, automation and STR solutions for kinship testing
Safety Data Sheets (1)
Kit Handbooks (2)
For ultrasensitive targeted next-generation sequencing (NGS) of DNA for Illumina NGS systems
For ultrasensitive targeted next-generation sequencing (NGS) of DNA for Ion Torrent NGS systems
Certificates of Analysis (1)

Publications

Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL;
Lung Cancer; 2018; 124 :154-159 2018 Aug 8 PMID:30268455
smCounter2: an accurate low-frequency variant caller for targeted sequencing data with unique molecular identifiers.
Xu C; Gu X; Padmanabhan R; Wu Z; Peng Q; DiCarlo J; Wang Y;
Bioinformatics; 2019; 35 (8):1299-1309 2019 Apr 15 PMID:30192920
Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG;
J Cancer Res Clin Oncol; 2018; 144 (11):2167-2175 2018 Sep 10 PMID:30203147
Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller.
Xu C; Nezami Ranjbar MR; Wu Z; DiCarlo J; Wang Y;
BMC Genomics; 2017; 18 (1):5 2017 Jan 3 PMID:28049435
Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF;
Am J Surg Pathol; 2018; 42 (11):1530-1540 2018 Nov PMID:30001242